D1 Capital Partners and by Kaiser Permanente led a $165m Series C round in PathAI, a global provider of artificial intelligence-powered technology for pathology, with participation from General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, Bristol-Myers Squibb Company, Labcorp and Merck Global Health Innovation Fund. "We have been following PathAI's journey and have been impressed by their growth and the impact they have made in the industry. We are excited to support their mission as they continue to expand their research in diagnostic development and AI- powered pathology," Daniel Sundheim, D1 Capital Partners Founder.